Recombinant Human Plasma Gelsolin
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Recombinant Human Plasma Gelsolin
- DrugBank Accession Number
- DB15746
- Background
Plasma gelsolin (pGSN) is a protein found in the blood of healthy individuals which scavenges compounds left over from damaged tissues.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Recombinant Enzymes - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- pGSN
- Plasma gelsolin
- Rhu-pGSN
- External IDs
- Recombinant Human Plasma Gelsolin
Pharmacology
- Indication
Not Available
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Not Available
- Mechanism of action
pGSN also enhances bacterial uptake and death by macrophages. It has positive effects on the immune system as it boosts clearing of pathogens and modulates inflammatory reactions; often pGSN is consumed in both serious infectious and non-infectious conditions. Its physiological effects thus make it a potential candidate for severe acute respiratory syndrome (ARDS) associated with COVID-19, as administration of recombinant protein is thought to supplement depleted levels of pGSN.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Tannous A, Levinson SL, Bolognese J, Opal SM, DiNubile MJ: Safety and Pharmacokinetics of Recombinant Human Plasma Gelsolin in Patients Hospitalized for Non-Severe Community-Acquired Pneumonia. Antimicrob Agents Chemother. 2020 Jul 20. pii: AAC.00579-20. doi: 10.1128/AAC.00579-20. [Article]
- Piktel E, Wnorowska U, Ciesluk M, Deptula P, Prasad SV, Krol G, Durnas B, Namiot A, Markiewicz KH, Niemirowicz-Laskowska K, Wilczewska AZ, Janmey PA, Reszec J, Bucki R: Recombinant Human Plasma Gelsolin Stimulates Phagocytosis while Diminishing Excessive Inflammatory Responses in Mice with Pseudomonas aeruginosa Sepsis. Int J Mol Sci. 2020 Apr 7;21(7). pii: ijms21072551. doi: 10.3390/ijms21072551. [Article]
- Yang Z, Bedugnis A, Levinson S, Dinubile M, Stossel T, Lu Q, Kobzik L: Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Penicillin-Susceptible and Penicillin-Resistant Pneumococcal Pneumonia. J Infect Dis. 2019 Sep 26;220(9):1498-1502. doi: 10.1093/infdis/jiz353. [Article]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Active Not Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1 1, 2 Completed Treatment Burns / Infection / Low Gelsolin / Traumas 1 1, 2 Completed Treatment Community Acquired Pneumonia (CAP) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on August 11, 2020 21:27 / Updated on August 13, 2020 07:02